Novo CEO expects patients to stay on Wegovy longer than older weight loss drugs

Novo Nordisk's (NOVOb.CO) CEO said on Tuesday he expects patients will stick with the company's popular obesity drug Wegovy for far longer than those using older treatments.

"We know from all medical interventions, stay time is not like a 100%... but I think we will see a significantly higher stay time than what we have seen so far on obesity treatment," said Lars Fruergaard Jorgensen at the JPMorgan Healthcare conference in San Francisco.